MyMD Pharmaceuticals Inc (MYMD) Actualités

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 8-K - Current report

MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

Common Stock Will Begin Trading on Split-Adjusted Basis on February 15, 2024 MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the...

Form 8-K - Current report

MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis

Company targets first quarter 2024 for trial initiation Potential to be first orally-administered TNF-α inhibitor treatment for RA MyMD...

Form 8-K - Current report

MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain

- Supera-CBD eased heat-related pain due to inflammation quickly and provided long-lasting pain relief lasting up to five hours - Results suggest...

Form 8-K - Current report

Form 8-K - Current report

MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023

- Company to share new positive, statistically significant results across Cohort 4 (1050mg) from Phase 2 study...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report